EOLS Company Profile and Key Details

EOLS has shown weak momentum, losing -12.31% over the past week and -20.94% over the past quarter, though year-to-date performance is down -23.91%. Short-term trend indicators are bullishly aligned (SMA20 0.71%, SMA50 -16.72%, SMA200 -37.97%). The stock’s 14-day RSI is 42.53 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.95% below its high and over 9.75% above its low. Average 10-day trading volume of 919.83 thousand shares is in line with the 3-month average of 866.08 thousand, indicating normal recent market interest.

Evolus, Inc. has 64.69 million shares outstanding. The public float is 50.60 million shares, elevated short interest at 21.30% of float. This equals 13.48 million shares. The short ratio is 14.62 days. Institutional investors hold 103.29% of the float. Insiders own 11.81%. Alphaeon Corp holds 8.66 million shares, Alphaeon 1 LLC has 4.21 million shares and Medytox Inc. has 3.38 million shares. Over the past six months, insider transactions show net selling. They sold 163.50 thousand shares across 4 transactions.

Evolus, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.05. This means the shares are trading below this model’s fair value.

Evolus, Inc. generated EPS of -$0.91 over the past year. Five-year average earnings growth is 23.91%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at $0.03. Next year's EPS is expected at $17.67. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $13.00. The high target offers 290.76% upside. The low target suggests 130.91% downside. The mean target is $17.00. This offers 201.95% upside. Evolus, Inc. earnings surprise history is a mixed track record. The quarter that ended May 04, 2026, missed forecasts by -67.33%. The prior quarter beat by -26.3%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in March 04, 2025.

Evolus, Inc. (NASDAQ:EOLS) closed at $5.63 USD, losing -$0.33 (-5.54%) from the previous close of $5.96. The stock is currently mid-range between its 52-week high and low $3.86 and $10.20. With a market capitalization of about $370.76 million, Evolus, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 858.33 thousand shares, in line with its 52-week average. Headquartered in Newport Beach, CA, Evolus, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David Moatazedi, the company employs approximately 350 people and listed since February 08, 2018. Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients.

Evolus, Inc. trades at a P/E ratio of -8.53, slightly below the S&P 500 average, with a price-to-sales ratio of 1.24 and a price-to-book ratio of -12.91 indicating negative book value, which may reflect financial stress. The P/FCF stands at -8.37, also below market averages.

Our AI price prediction model suggests that Evolus, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.26%, with price expected at $5.87 by July 29, 2026, within a range of $5.66 to $6.07 3-Month Outlook: Projected fall of -22.02%, reaching $4.39 by October 12, 2026, with a range of $3.77 to $4.77. 1-Year Outlook: Projected gain of 300.71%, with price at $22.56 by July 15, 2027, within a range of $10.15 to $34.10.

Evolus, Inc. (NASDAQ:EOLS) shares are down -23.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Evolus, Inc. trading at a premium to the broader market with a P/E of -8.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.98, suggesting 254.88% upside. Our AI forecast model points to short-term strength (4.26% over two weeks), a medium-term fall (-22.02% over three months), and a longer-term gain (300.71% over one year), with expected trading ranges indicating moderate volatility.